Results of a Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-Ranging, Safety, and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine in Antiretroviral-Naive Subjects.
Sanne, Ian *; Piliero, Peter +; Squires, Kathleen ++; Thiry, Alexandra [S]; Schnittman, Steven [S]; AI424-007 Clinical Trial Group
JAIDS Journal of Acquired Immune Deficiency Syndromes.
32(1):18-29, January 1, 2003.
(Format: HTML, PDF)